SCM
KZR

Soleus Capital Management’s Kezar Life Sciences KZR Stock Holding History

Soleus Capital Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-25,200
Closed -$2.08M – 82
2022
Q2 		$2.08M Buy
+25,200
New +$2.22M 0.33% 59

Other funds holding KZR

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Soleus Capital Management's KZR Position: Q3 2022 in Review

Soleus Capital Management sold out of Kezar Life Sciences (KZR) in Q3 2022, closing a stake of 25,200 shares — an estimated $2.08M sold.

Soleus Capital Management first reported a position in KZR in Q2 2022 and held it in 1 quarter. The position peaked at $2.08M in Q2 2022. 132 funds tracked by Wall St. Rank hold KZR as of Q3 2022.

  • Soleus Capital Management reported no remaining Kezar Life Sciences position as of Q3 2022 after selling out during the quarter.
  • Soleus Capital Management sold 25,200 Kezar Life Sciences shares in Q3 2022, an estimated $2.08M.
  • Soleus Capital Management first reported a position in Kezar Life Sciences in Q2 2022 and held it in 1 quarter.
  • Soleus Capital Management's Kezar Life Sciences position peaked at $2.08M in Q2 2022.
  • 132 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2022.

Based on Soleus Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.